System for the biocontrol of pathogens in aquaculture and other animal systems
The inventive technology relates to novel paratransgenic strategies for the biocontrol of pathogens in animal systems using interfering RNA molecules expressed in genetically modified bacteria that may be configured to colonize a target host. In one preferred embodiment, the invention includes novel paratransgenic strategies for the biocontrol of pathogens in aquatic organisms raised in aquaculture environments.
1. A composition for the biocontrol of white spot syndrome comprising:
a genetically modified probiotic bacteria that expresses at least one heterologous inhibitory polynucleotide encoded by a nucleic acid selected from the group consisting of: SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3, wherein said at least one heterologous inhibitory polynucleotide is a double stranded RNA polynucleotide molecule (dsRNA) that targets an essential gene in a white spot syndrome virus (WSSV), wherein said essential gene is selected from the group consisting of: wsv477, vp28, and vp19.
2. The composition of claim 1 , wherein said genetically modified probiotic bacteria comprises a genetically modified probiotic bacteria selected from the group consisting of: Bacillus subtilis , and Enterobacter.
3. The composition of claim 1 , wherein said genetically modified probiotic bacteria comprises an RNaseIII deficient genetically modified probiotic bacteria.
4. The composition of claim 1 , wherein said genetically modified probiotic bacteria is added to a commercial feed forming a treated feed for an aquatic animal that is infected with WSSV, or susceptible to infection by WSSV.
5. The composition of claim 4 , wherein said at least one heterologous inhibitory polynucleotide selected from the group of nucleic acid sequences consisting of SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3, comprises at least one heterologous inhibitory polynucleotide selected from the group of nucleic acid sequences consisting of: at least one heterologous inhibitory polynucleotide having 95% homology with SEQ ID NO. 1; at least one heterologous inhibitory polynucleotide having at least 95% homology with SEQ ID NO. 2, and at least one heterologous inhibitory polynucleotide having 95% homology with SEQ ID NO. 3.
6. The composition of claim 5 , wherein the biocontrol of white spot syndrome comprises the biocontrol of white spot syndrome in shrimp.
7. The composition of claim 6 , wherein said shrimp comprise shrimp raised in an aquaculture environment.
8. The composition of claim 7 , wherein said genetically modified probiotic bacteria is transmitted to a shrimp progeny through vertical transmission.
9. The composition of claim 8 , and further comprising a therapeutically effective amount of said genetically modified probiotic bacteria administered to said shrimp raised in an aquaculture environment such that said heterologous inhibitory polynucleotide downregulates expression of said essential gene in WSSV and further results in a reduction in mortality due to WSSV in said shrimp raised in an aquaculture environment that are administered a therapeutically effective amount of said probiotic bacteria.
10. A composition for the biocontrol of white spot syndrome in shrimp comprising:
a genetically modified probiotic enteric bacteria that expresses at least one heterologous inhibitory polynucleotide selected from the group nucleic acids sequences consisting of: SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3, wherein said at least one heterologous inhibitory polynucleotide is a double stranded RNA polynucleotide molecule (dsRNA) that targets an essential gene in a white spot syndrome virus (WSSV), wherein said essential gene is selected from the group consisting of: wsv477, vp28, and vp19.
11. The composition of claim 10 , wherein said genetically modified probiotic enteric bacteria comprises a genetically modified probiotic enteric bacteria selected from the group consisting of: Bacillus subtilis , and Enterobacter bacteria.
12. The composition of claim 11 , wherein said genetically modified probiotic enteric bacteria comprises an RNaseIII deficient genetically modified probiotic enteric bacteria.
13. The composition of claim 10 , wherein said genetically modified probiotic enteric bacteria is added to a commercial shrimp feed forming a treated feed for shrimp that is infected with WSSV, or susceptible to infection by WSSV.
14. The composition of 13 , wherein said at least one heterologous inhibitory polynucleotide selected from the group of nucleic acid sequences consisting of SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3, comprises at least one heterologous inhibitory polynucleotide selected from the group consisting of: at least one heterologous inhibitory polynucleotide having 95% homology with SEQ ID NO. 1; at least one heterologous inhibitory polynucleotide having 95% homology with SEQ ID NO. 2, and at least one heterologous inhibitory polynucleotide having 95% homology with SEQ ID NO. 3.
15. The composition of 10 , wherein said shrimp comprise shrimp raised in an aquaculture environment.
16. The composition of 15 wherein said genetically modified probiotic enteric bacteria is transmitted to shrimp progeny through vertical transmission.
17. The composition of 16 , and further comprising a therapeutically effective amount of said genetically modified probiotic enteric bacteria administered to said shrimp raised in an aquaculture environment such that said heterologous inhibitory polynucleotide downregulating expression of said essential gene in a WSSV, an further results in a reduction in mortality due to WSSV in said shrimp raised in an aquaculture environment.